FULL APPROVAL

FDA approves once-weekly subcutaneous LEQEMBI IQLIK for early Alzheimer's

The approval lets patients start lecanemab with a 15-second weekly injection instead of an IV infusion, backed by exposure data showing the shot matches IV dosing.

By AppliedXLJuly 13, 2026Trial NCT03887455

Executive Summary

The FDA approved a subcutaneous, self-administered starting regimen for lecanemab, converting a drug that previously required infusion visits from day one into one patients can begin at home.
The approval leans on exposure-matching data from the drug's long-term extension study rather than a new placebo-controlled efficacy trial, so the bar it had to clear was pharmacologic equivalence to the existing IV regimen, not a fresh demonstration of benefit.
The underlying efficacy and safety case still rests on the original Phase 3 result that supported the drug's initial approval, and the amyloid-clearance mechanism remains one of only a handful validated in this disease so far.
Direct comparators on this target and mechanism are limited to a small set of amyloid-targeting antibodies, and the format shift gives lecanemab a distribution advantage those programs do not yet claim.

The decision

Eisai Co., Ltd. and Biogen Inc. said the FDA approved a supplemental Biologics License Application covering a once-weekly subcutaneous lecanemab-irmb injection, brand name LEQEMBI IQLIK, as an initiation dose for adults with mild cognitive impairment or mild dementia due to Alzheimer's disease. The approved initiation regimen is 500 mg given once weekly as two 250 mg injections, each delivered in about 15 seconds, administered by autoinjector. The same device can also deliver a 360 mg weekly maintenance dose after 18 months of IV or subcutaneous treatment, and patients can switch between IV and subcutaneous administration during the course of therapy. Eisai said U.S. launch of the initiation-dose version is planned for late August 2026. FDA

The evidence behind it

The approval traces back to Eisai's completion of a rolling BLA submission in October 2024, which sought clearance for subcutaneous maintenance dosing and was based on data from the Phase 3 Clarity AD open-label extension and pharmacokinetic modeling rather than a new controlled trial. That earlier submission had drawn a PDUFA action date of January 25, 2025, under Fast Track designation. The initiation-dose approval that followed rests on sub-studies within the same Clarity AD long-term extension, which found that once-weekly subcutaneous administration achieved exposure equivalent to intravenous dosing, supporting comparable efficacy and amyloid-clearance biomarker effects. The rate of ARIA-E, a swelling-type adverse event associated with anti-amyloid antibodies, was expected to be comparable between the subcutaneous and IV routes, and injection-site reactions with the subcutaneous form were mostly localized. Eisai+1

The underlying trial

That evidence chain runs back to the registrational Clarity AD study, NCT03887455, a Phase 3, placebo-controlled trial in 1,795 analyzed participants with early Alzheimer's disease. The trial showed lecanemab slowed disease progression at 18 months, with a CDR-SB difference of -0.45 versus placebo (P=0.00005), and met its primary and key secondary endpoints, with safety signals including ARIA and intracranial hemorrhage consistent with the drug class. Howard Fillit, Co-Founder and Chief Science Officer Emeritus of the Alzheimer's Drug Discovery Foundation, said the initiation-dose approval marks a shift because "for the first time, patients and their care partners have choice in how anti-amyloid treatment is delivered". The trial itself remains Active, not recruiting, with its primary completion date pushed to June 30, 2029 after a series of extensions from an original 2022 target, reflecting the long-term extension phase that generated the subcutaneous exposure data now supporting label expansion. NCT03887455+1

Where lecanemab sits in the field

Amyloid-beta protofibril clearance remains a narrow mechanism class in early Alzheimer's disease: two active trials, including Clarity AD itself, are studying that specific target in this indication, alongside a small set of other amyloid-targeting antibodies such as donanemab and remternetug that share the target and modality. Trial activity specifically against this target in this indication has slowed, with none of the newer trials in the broader landscape count against nine older ones targeting the same mechanism. The subcutaneous initiation option does not change lecanemab's underlying efficacy claim; it changes how many patients can access and stay on that established regimen without recurring infusion visits. NCT03887455

This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.